ArticleClinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology2025
Altered cortical excitability in tuberous sclerosis and the effect of mTOR inhibitors: An intracranial electrical stimulation study.
Article in Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveWe used electrical stimulation mapping (ESM) of functional responses, after-discharges (ADs), and unwanted electrical stimulation-induced seizures (EIS) to explore differences in cortical excitability in tuberous sclerosis complex (TSC) patients on mTOR inhibitors, TSC patients not on mTOR inhibitors, and drug-resistant epilepsy (DRE) of unknown etiology.
methodsIn 20 patients with TSC and 10 patients with DRE of unknown etiology, incidence and current thresholds of physiologic (language and motor) and pathologic (ADs, EIS) responses were analyzed using mixed effects models against disease phenotype (TSC vs unknown) and use of mTOR inhibitors.
resultsPatients with TSC showed a higher incidence and required a lower threshold current to elicit motor responses and ADs compared to those with DRE of unknown etiology. In TSC patients, mTOR inhibitors increased the threshold for motor responses and ADs, and decreased the incidence of face motor responses, language responses, and ADs.
conclusionsTSC patients exhibit higher physiologic and pathologic cortical excitability evidenced by a higher incidence and lower current thresholds of ESM responses, which appears to be mitigated by mTOR inhibitors. SIGNIFICANCE: To our knowledge, this is the first study providing direct intracranial evidence for altered cortical excitability in TSC and the corrective effect of mTOR inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.